Silmitasertib (CX-4945) is a a potent and selective inhibitor of CK2 (casein kinase 2) [4-5
]. CX-4945 is described in the same article as CX-5011
inhibition of CK2, was found to produce an in vitro
antiviral effect (IC50
= 2.34 μM;) [2
]. In conjunction with data supporting a physical interaction [3
] and co-localization of CK2 with SARS-CoV-2 N protein, and evidence of potential role of CK2 in remodeling extracellular matrix upon infection [2
], it can be hypothesised that the CK2 pathway is hijacked by SARS-CoV-2. Thus, it makes pharmacological sense that silmitasertib should be considered for investigation as an anti-SARS-CoV-2 therapeutic.